GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2007

Compendia Bioscience Signs Oncomine Licensing Agreement with AstraZeneca

  • Compendia Bioscience licensed Oncomine™, the company’s compendium of oncology gene expression profiles and analysis tools, to AstraZeneca. The firm will conduct a year-long pilot to evaluate the long-term role of this product in its cancer research programs.

    This licensing agreement gives AstraZeneca access to Oncomine Concepts Edition (OCM), a value-added product extension of Oncomine that reportedly combines nearly 7,000 proprietary cancer gene signatures with 11,000 gene, protein, drug, and pathway signatures collected from the literature and other public sources.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?